Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Syros Pharmaceuticals, Inc. (SYRS) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 8-K Quarterly results
08/11/2023 8-K Termination of a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/02/2023 4 Roth David (Chief Medical Officer) has filed a Form 4 on Syros Pharmaceuticals, Inc.
Txns: Sold 7,348 shares @ $3.95, valued at $29k
07/31/2023 144 Form 144 - Report of proposed sale of securities:
07/21/2023 8-K Quarterly results
07/18/2023 4 Olson Eric R (Chief Scientific Officer) has filed a Form 4 on Syros Pharmaceuticals, Inc.
Txns: Sold 689 shares @ $3.5, valued at $2.4k
07/17/2023 144 Form 144 - Report of proposed sale of securities:
06/02/2023 4 Young Richard A (Director) has filed a Form 4 on Syros Pharmaceuticals, Inc.
Txns: Granted 4,000 shares @ $0
Granted 6,000 options to buy @ $3.7, valued at $22.2k
06/02/2023 4 WIRTH PETER (Director) has filed a Form 4 on Syros Pharmaceuticals, Inc.
Txns: Granted 4,000 shares @ $0
Granted 6,000 options to buy @ $3.7, valued at $22.2k
06/02/2023 4 TYSON TIMOTHY (Director) has filed a Form 4 on Syros Pharmaceuticals, Inc.
Txns: Granted 4,000 shares @ $0
Granted 6,000 options to buy @ $3.7, valued at $22.2k
06/02/2023 4 OH ANDREW M. (Director) has filed a Form 4 on Syros Pharmaceuticals, Inc.
Txns: Granted 4,000 shares @ $0
Granted 6,000 options to buy @ $3.7, valued at $22.2k
06/02/2023 4 Fanucci Marsha (Director) has filed a Form 4 on Syros Pharmaceuticals, Inc.
Txns: Granted 4,000 shares @ $0
Granted 6,000 options to buy @ $3.7, valued at $22.2k
06/02/2023 4 Eckhardt Sue Gail (Director) has filed a Form 4 on Syros Pharmaceuticals, Inc.
Txns: Granted 4,000 shares @ $0
Granted 6,000 options to buy @ $3.7, valued at $22.2k
06/02/2023 4 Dunsire Deborah (Director) has filed a Form 4 on Syros Pharmaceuticals, Inc.
Txns: Granted 6,000 options to buy @ $3.7, valued at $22.2k
Granted 4,000 restricted stock units @ $0
06/02/2023 4 Alles Mark J (Director) has filed a Form 4 on Syros Pharmaceuticals, Inc.
Txns: Granted 6,000 options to buy @ $3.7, valued at $22.2k
Granted 4,000 restricted stock units @ $0
06/02/2023 4 AKKARAJU SRINIVAS (Director) has filed a Form 4 on Syros Pharmaceuticals, Inc.
Txns: Granted 6,000 options to buy @ $3.7, valued at $22.2k
Granted 4,000 restricted stock units @ $0
05/25/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Slide Presentation, dated May 2023",
"Data Demonstrate Encouraging Clinical Activity in Patients with PDAC Syros will present updated data from the single agent dose escalation portion and the gemcitabine/nab-paclitaxel combination safety lead-in portion of the Phase 1/1b trial. The maximum tolerated dose of SY-5609 as a single-agent was 10 mg using a 7 day on/7 day off dosing schedule. For the doublet, the MTD was 5 mg SY-5609 plus 1000 mg gemcitabine. A MTD was not established using the triplet cohort of SY-5609, gemcitabine and nab-paclitaxel. Each of the single-agent, doublet and the triplet regimens were generally well-tolerated with mostly low-grade events. Encouraging clinical activity was observed at the MTDs with SY-5609 both as a single-agent and in combination . Among the three response evaluable patients with selec..."
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/01/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/01/2023 EFFECT Form EFFECT - Notice of Effectiveness:
04/21/2023 ARS Form ARS - Annual Report to Security Holders:
04/21/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/21/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/20/2023 4/A Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
04/20/2023 4/A Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
04/06/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
04/04/2023 4 Haas Jason (CFO) has filed a Form 4 on Syros Pharmaceuticals, Inc.
Txns: Paid exercise price by delivering 623 shares @ $2.58, valued at $1.6k
Exercised 2,000 restricted stock units @ $0
04/04/2023 4 Chee Conley (Chief Commercial Officer) has filed a Form 4 on Syros Pharmaceuticals, Inc.
Txns: Paid exercise price by delivering 658 shares @ $2.58, valued at $1.7k
Exercised 2,000 restricted stock units @ $0
04/04/2023 4 Roth David (Chief Medical Officer) has filed a Form 4 on Syros Pharmaceuticals, Inc.
Txns: Paid exercise price by delivering 623 shares @ $2.58, valued at $1.6k
Exercised 2,000 restricted stock units @ $0
04/04/2023 4 Stephens Kristin (Chief Development Officer) has filed a Form 4 on Syros Pharmaceuticals, Inc.
Txns: Paid exercise price by delivering 623 shares @ $2.58, valued at $1.6k
Exercised 2,000 restricted stock units @ $0
04/04/2023 4 Olson Eric R (Chief Scientific Officer) has filed a Form 4 on Syros Pharmaceuticals, Inc.
Txns: Paid exercise price by delivering 623 shares @ $2.58, valued at $1.6k
Exercised 2,000 restricted stock units @ $0
04/04/2023 4 Simonian Nancy A (President & CEO) has filed a Form 4 on Syros Pharmaceuticals, Inc.
Txns: Paid exercise price by delivering 1,852 shares @ $2.58, valued at $4.8k
Exercised 6,000 restricted stock units @ $0
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy